Figure 3 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib

<jats:p>&lt;p&gt;Correlations between the expression of &lt;i&gt;SLFN11&lt;/i&gt; and plasma cell markers and &lt;i&gt;SLFN11&lt;/i&gt; transcriptional regulation in multiple myeloma (MM). &lt;b&gt;A,&lt;/b&gt; Scatter plots demonstrating positive correlations between &lt;i&gt;SLFN11&lt;/i&gt; expression and plasma cell markers (&lt;i&gt;n&lt;/i&gt; = 844 MM samples from the MMRF CoMMpass study. &lt;b&gt;B,&lt;/b&gt; Heatmap displaying the mRNA expression of the top 12 transcription factors and epigenetic enzymes with the strongest correlation with &lt;i&gt;SLFN11&lt;/i&gt; expression (samples are from the MMRF CoMMpass study). Red, high expression; blue, low expression. &lt;b&gt;C,&lt;/b&gt; Scatter plot highlighting the positive correlation between &lt;i&gt;SLFN11&lt;/i&gt; and &lt;i&gt;ZBTB38&lt;/i&gt; expression. &lt;b&gt;D,&lt;/b&gt; Representative Western blots showing time-dependent effects of super-enhancer inhibitors on SLFN11, ZBTB38, and IRF2 protein levels in MM cell lines. Left, KMS-34 cells treated with JQ1 (BET inhibitor, 500 nmol/L) or THZ1 (CDK7 inhibitor, 200 nmol/L) for 0, 12, 24, and 48 hours. Right, KMS-27 cells treated with JQ1 (1 μmol/L) or THZ1 (50 nmol/L) for the same time points. β-Actin serves as a loading control. TF, transcription factor.&lt;/p&gt;</jats:p>